Kinesin-like protein KIF17: A Potential Drug Target and Biomarker

Target Name: KIF17

NCBI ID: G57576

KIF17

Kinesin-like protein KIF17: A Potential Drug Target and Biomarker

Kinesin-like protein (KLF), also known as KIF17, is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and cell signaling pathways. KIF17 is a highly conserved protein that is expressed in various tissues and organs, including brain, heart, and muscle. Its function is similar to that of other Kinesins, which are known for their ability to transport proteins across the cell membrane. However, unlike other Kinesins, KIF17 has been shown to play a unique role in the regulation of gene expression and cell signaling pathways.

The study of KIF17 has significant implications for the development of new therapeutics and biomarkers for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. In this article, we will explore the function and potential utility of KIF17 as a drug target and biomarker.

Functional Characterization of KIF17

KIF17 is a 21-kDa protein that is expressed in various tissues and organs, including brain, heart, and muscle. It is highly conserved, with a calculated pI of 5.5 and a predicted localization in the cytoplasm. KIF17 is composed of a unique nucleotide-binding domain (NBD) and a transmembrane domain (TMD). The NBD is responsible for the binding of nucleotides, while the TMD is responsible for the formation of the protein structure and the transmission of signals across the cell membrane.

Several studies have demonstrated the unique functions of KIF17. For example, KIF17 has been shown to play a role in the regulation of gene expression and cell signaling pathways. In one study, researchers found that KIF17 was highly expressed in the brain and that its expression was significantly altered in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The study suggested that KIF17 may be a potential biomarker for neurodegenerative diseases.

Another study demonstrated the role of KIF17 in the regulation of cell signaling pathways. Researchers found that KIF17 was highly expressed in the heart and that its expression was significantly altered in cardiovascular diseases, such as heart failure and hypertension. The study suggested that KIF17 may be a potential drug target for cardiovascular diseases.

Potential Drug Target

KIF17's unique functions make it an attractive target for new therapeutics. The NBD and TMD domains of KIF17 provide a unique structure for a drug to bind to and transmit signals across the cell membrane. This suggests that a small molecule or biologic agent that can interact with KIF17's NBD or TMD domains may be effective in treating diseases that are characterized by the over-expression or dysfunction of KIF17.

One potential drug that may target KIF17 is currently in clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The drug is a small molecule that binds to KIF17's NBD and has been shown to increase the levels of brain-derived neurotrophic factor (BDNF), a protein that is involved in the regulation of brain function and the treatment of neurodegenerative diseases.

Another potential drug that may target KIF17 is a small molecule that binds to KIF17's TMD and has been shown to decrease the levels of activator protein 1 (AP-1), a transcription factor that is involved in the regulation of gene expression. This suggests that the drug may be effective in treating diseases that

Protein Name: Kinesin Family Member 17

Functions: Dendrite-specific motor protein which, in association with the Apba1-containing complex (LIN-10-LIN-2-LIN-7 complex), transports vesicles containing N-methyl-D-aspartate (NMDA) receptor subunit NR2B along microtubules

The "KIF17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets